BridgeMD
New treatment option for Cervical Cancer
Official title Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
ClinicalTrials.gov ID: NCT06952660
What this study is testing
What is TIVDAK?
TIVDAK is an investigational medicine, given as a monthly infusion into a vein, being studied as a potential treatment for cervical cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, women only
You may be able to join if
- Must have recurrent or metastatic cervical cancer with disease progression on or after chemotherapy
- Treating physician has determined that treatment with Tivdak is appropriate for the participant according to US Prescribing Information
- Must sign an informed consent form indicating that the participant understands the purpose and procedures required for the study and are willing to...
- Must be willing to undergo repeated ocular assessments as required by the study and regular clinic visits according to local standard practice of the...
- Must agree to use effective contraception according to the US Prescribing Information
You likely can't join if
- Active ocular disease at baseline per investigator assessment
- Previous treatment with Tivdak
- Previous administration of an investigational drug within 30 days
- Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may...
The study team makes the final eligibility decision.
Where it's taking place
- Phoenix, Arizona, United States
- Scottsdale, Arizona, United States
- Tempe, Arizona, United States
- Aventura, Florida, United States
- Bonita Springs, Florida, United States
- Bradenton, Florida, United States
- Cape Coral, Florida, United States
- Coral Springs, Florida, United States
- Daytona Beach, Florida, United States
- Deerfield Beach, Florida, United States
- Fleming Island, Florida, United States
- Fort Lauderdale, Florida, United States
- Fort Myers, Florida, United States
- Miami, Florida, United States
- Miami Beach, Florida, United States
- N. Venice, Florida, United States
- Naples, Florida, United States
- Orlando, Florida, United States
- Port Charlotte, Florida, United States
- Sarasota, Florida, United States
+ 36 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Phoenix, Arizona, United States; Scottsdale, Arizona, United States; Tempe, Arizona, United States; Aventura, Florida, United States; Bonita Springs, Florida, United States; Bradenton, Florida, United States and 50 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.